COMPARISON OF RISS AND IMWG RISK STRATIFICATION GUIDELINES WITH GENE EXPRESSION PROFILE SKY92 IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS; RESULTS FROM THE PROMMIS TRIAL
Author(s): ,
Parameswaran Hari
Affiliations:
Medical College of Wisconsin,Milwaukee,United States
,
Susanne Lentzsch
Affiliations:
New York Presbyterian Hospital - Columbia,New York,United States
,
David Siegel
Affiliations:
Hackensack University Medical Center,Hackensack,United States
,
Saad Z. Usmani
Affiliations:
Levine Cancer Institute,Charlotte,United States
,
Binod Dhakal
Affiliations:
Medical College of Wisconsin,Milwaukee,United States
,
Adriana Rossi
Affiliations:
Weill Cornell Medicine,New York,United States
,
Cara Rosenbaum
Affiliations:
Weill Cornell Medicine,New York,United States
,
Siyang Leng
Affiliations:
New York Presbyterian Hospital - Columbia,New York,United States
,
Divaya Bhutani
Affiliations:
New York Presbyterian Hospital - Columbia,New York,United States
,
Manisha Bhutani
Affiliations:
Levine Cancer Institute,Charlotte,United States
,
Noa Biran
Affiliations:
Hackensack University Medical Center,Hackensack,United States
,
David Vesole
Affiliations:
MedStar Georgetown University Hospital,Georgetown,United States
,
Lisette Stork-Sloots
Affiliations:
Medex15,Antwerp,Belgium
,
Femke de Snoo
Affiliations:
Medex15,Amsterdam,Netherlands
,
Belinda Dumee
Affiliations:
SkylineDx,Rotterdam,Netherlands
,
Martin H. van Vliet
Affiliations:
SkylineDx,Rotterdam,Netherlands
Ruben Niesvizky
Affiliations:
Weill Cornell Medicine,New York,United States
EHA Library. Hari P.
Jun 14, 2019; 266419
Prof. Parameswaran Hari
Prof. Parameswaran Hari
Contributions
Abstract

Abstract: PF620

Type: Poster Presentation

Presentation during EHA24: On Friday, June 14, 2019 from 17:30 - 19:00

Location: Poster area

Background

Multiple Myeloma (MM) is recognized as a heterogeneous group of patients with varying response and outcome of their disease, associated with various risk factors including genetic abnormalities. Genetic abnormalities are important factors for risk stratification guidelines such as outlined in the IMWG consensus. High risk gene expression profiling results are included in these guidelines for stratifying patients as high risk. One such gene expression profile is the SKY92; it is a 92-gene prognostic signature which classifies MM patients into a “high” or “standard” risk group. It has been reported to be a robust predictor for Overall Survival (OS) as well as Progression Free Survival (PFS) (Kuiper 2012, Kuiper 2015). The PRospective Observational Multiple Myeloma Impact Study (PROMMIS) trial (NCT02911571) assess the impact of SKY92 on treatment intention.

Aims

The aim of this current sub-study is to compare SKY92 risk results with rISS and the IMWG consensus on risk stratification in PROMMIS patients and to determine the potential impact of gene expression profile determined risk implementation in clinical practice.

Methods

Patients with MM according to the IMWG criteria and an ECOG performance status ≤ 3 had their BM aspirate analyzed using the MMprofiler with SKY92. Physicians completed questionnaires capturing treatment intention and MM risk prior to and post receiving the SKY92 result. Genetic abnormalities were determined in local laboratories. Genetic abnormalities defined as high risk in the IMWG consensus: t(4;14), del17p, and gain1q. The IMWG consensus (Chng 2014) and rISS classification (Palumbo 2015) were compared with SKY92 risk classification.

Results

Thirty-eight patients have been enrolled in the PROMMIS trial so far. Prior to SKY92 physicians classified 22 patients (58%) as high risk. SKY92 classified 14 patients (37%) as high risk.  

The majority of patients (n=27; 71%) were r-ISS stage II, of whom 10 were SKY92 high risk. Eight patients were r-ISS I, of whom 2 were SKY92 high risk. Only one patient was r-ISS stage III; who was also classified as high risk by SKY92.

Eighteen patients carried one or more high risk abnormalities as defined in the IMWG consensus: t(4;14) (n=1), del17p (n=5), and gain1q (n=13). SKY92 classified 8 of these patients as high risk and the other 10 as standard risk. Twenty patients had no IMWG consensus high risk genetic abnormality detected and SKY92 classified 6 of these patients as high risk.

Physician risk classification and treatment intention changed in 16 out of 38 (42%) patients after receiving SKY92. For 24 patients (63%) the physician indicated the SKY92 result to be helpful.  Furthermore, the treatment intention for 34 (89%) of patients was in line with the SKY92 result.

Conclusion

Risk stratification by rISS and IMWG consensus missed a substantial number of high risk MM patients that could be identified using SKY92.

Overall, physician risk classification changed for 42% of patients after receiving the SKY92 result. The final treatment intention by the physician after knowing all factors including SKY92 was in agreement with SKY92 for 34 out of 38 patients

This underlines the relevance and need for assessment of SKY92 in MM patients, and associated risk stratified treatment paradigm.

Session topic: 14. Myeloma and other monoclonal gammopathies - Clinical

Keyword(s): Gene expression profile, Multiple myeloma, Prognosis

Premium Sponsors
Major Sponsors

By continuing to browse or by clicking “Accept Terms & all Cookies”, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies